Classification Based on the Structural Form of Bispecific Antibodies

Q: Classification Based on the Structural Form of Bispecific Antibodies

1) IgG-like bispecific antibody: IgG-like BsAb has an Fc part and Fc-mediated effect functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP). The Fc part of the antibody is helpful for purification and improves its solubility and stability in the later stages. The relative molecular weight of IgG-like BsAb is larger, and the Fc part binds to the FcRn receptor, increasing the antibody's serum half-life. Antibody-like structures include Triomabs/quadroma, DVD-LG (dual variable domain Ig), CrossMAb, Two-in-one IgG, and scFv2-Fc. 2) Non-IgG-like bispecific antibody: Non-IgG -like BsAb lacks Fc fragments and functions therapeutically only through antigen binding. It is characterized by low immunogenicity, ease of production, and small molecular weight. Due of its relatively small molecular weight, it exhibits higher permeability in tumor tissue, resulting in more significant therapeutic effects. These BsAbs come in various forms, including TandAb (tandem diabody), scFv-HSA-scFv, BiTE (bi-specific T-cell engager), and DART (dual Affinity retargeting), and Nanobody.

Question

Accepted Answer

1) IgG-like bispecific antibody:

IgG-like BsAb has an Fc part and Fc-mediated effect functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP). The Fc part of the antibody is helpful for purification and improves its solubility and stability in the later stages. The relative molecular weight of IgG-like BsAb is larger, and the Fc part binds to the FcRn receptor, increasing the antibody's serum half-life. Antibody-like structures include Triomabs/quadroma, DVD-LG (dual variable domain Ig), CrossMAb, Two-in-one IgG, and scFv2-Fc.

2) Non-IgG-like bispecific antibody:

Non-IgG -like BsAb lacks Fc fragments and functions therapeutically only through antigen binding. It is characterized by low immunogenicity, ease of production, and small molecular weight. Due of its relatively small molecular weight, it exhibits higher permeability in tumor tissue, resulting in more significant therapeutic effects. These BsAbs come in various forms, including TandAb (tandem diabody), scFv-HSA-scFv, BiTE (bi-specific T-cell engager), and DART (dual Affinity retargeting), and Nanobody.